Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. News
Eton Pharmaceuticals, Inc. Quantitative Score
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Eton Pharmaceuticals, Inc. Financials
Table Compare
Compare ETON metrics with: | |||
|---|---|---|---|
Earnings & Growth | ETON | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ETON | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ETON | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ETON | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Eton Pharmaceuticals, Inc. Income
Eton Pharmaceuticals, Inc. Balance Sheet
Eton Pharmaceuticals, Inc. Cash Flow
Eton Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Eton Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Mr. Sean E. Brynjelsen | President, Chief Executive Officer & Director |
| Mr. David C. Krempa | Chief Business Officer |
| Mr. James R. Gruber CPA | Chief Financial Officer, Treasurer & Secretary |
| Ms. Ipek Erdogan-Trinkaus | Chief Commercial Officer |
| Danka Radosavljevic | Senior Vice President of Quality & Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Sean E. Brynjelsen | President, Chief Executive Officer & Director | Male | 1972 | 1.12M |
| Mr. David C. Krempa | Chief Business Officer | Male | 1989 | 647.85K |
| Mr. James R. Gruber CPA | Chief Financial Officer, Treasurer & Secretary | Male | 1972 | 647.85K |
| Ms. Ipek Erdogan-Trinkaus | Chief Commercial Officer | Female | 1982 | 435.94K |
| Danka Radosavljevic | Senior Vice President of Quality & Operations | -- |
Eton Pharmaceuticals, Inc. Insider Trades
| Date | 12 Jun |
| Name | Krempa David |
| Role | Chief Business Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 16977 |
| Date | 13 Jun |
| Name | Krempa David |
| Role | Chief Business Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 6800 |
| Date | 16 Jun |
| Name | Krempa David |
| Role | Chief Business Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 10223 |
| Date | 10 Jun |
| Name | Opaleye Management Inc. |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 5000 |
| Date | 10 Jun |
| Name | Opaleye Management Inc. |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2930 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 12 Jun | Krempa David | Chief Business Officer | Disposed | S-Sale | 16977 |
| 13 Jun | Krempa David | Chief Business Officer | Disposed | S-Sale | 6800 |
| 16 Jun | Krempa David | Chief Business Officer | Disposed | S-Sale | 10223 |
| 10 Jun | Opaleye Management Inc. | 10 percent owner | Acquired | P-Purchase | 5000 |
| 10 Jun | Opaleye Management Inc. | 10 percent owner | Acquired | P-Purchase | 2930 |